Aclidinium Bromide is a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease. Reference standards of Aclidinium Bromide API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
No Data Found